Royalty Pharma plc Total Liabilities
Royalty Pharma plc (RPRX) had Total Liabilities of $10.03 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-05
- 2026-06-30: Liabilities $10.03B.
- 2026-03-31: Liabilities $9.88B.
- 2025-12-31: Liabilities $9.91B.
- 2025-09-30: Liabilities $9.73B.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $10.03B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $9.88B 10-Q · filed 2026-05-06 |
| 2025-12-31 | $9.91B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $9.73B 10-Q · filed 2025-11-05 |
| 2025-06-30 | $8.82B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $7.82B 10-Q · filed 2025-05-08 |
| 2024-12-31 | $7.88B 10-K · filed 2026-02-11 |
| 2024-09-30 | $7.78B 10-Q · filed 2024-11-06 |
| 2024-06-30 | $7.90B 10-Q · filed 2024-08-08 |
| 2024-03-31 | $6.27B 10-Q · filed 2024-05-09 |
| 2023-12-31 | $6.30B 10-K · filed 2025-02-12 |
| 2023-09-30 | $6.27B 10-Q · filed 2023-11-08 |
| 2023-06-30 | $7.31B 10-Q · filed 2023-08-08 |
| 2023-03-31 | $7.25B 10-Q · filed 2023-05-09 |
| 2022-12-31 | $7.29B 10-K · filed 2024-02-15 |
| 2022-09-30 | $7.26B 10-Q · filed 2022-11-08 |
| 2022-06-30 | $7.33B 10-Q · filed 2022-08-04 |
| 2022-03-31 | $7.24B 10-Q · filed 2022-05-05 |
| 2021-12-31 | $7.27B 10-K · filed 2023-02-15 |
| 2021-09-30 | $7.35B 10-Q · filed 2021-11-10 |
| 2021-06-30 | $6.11B 10-Q · filed 2021-08-11 |
| 2021-03-31 | $6.08B 10-Q · filed 2021-05-11 |
| 2020-12-31 | $6.12B 10-K · filed 2022-02-15 |
| 2020-09-30 | $6.19B 10-Q · filed 2020-11-12 |
| 2020-06-30 | $6.29B 10-Q · filed 2020-08-12 |
| 2019-12-31 | $6.31B 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |